Adamis Pharmaceuticals Corp (ADMP) Shares Up Big on Small Volume as Investors Anticipate New Drug Application Submission


The stock is up 15.11% or $0.74 today, hitting $5.66 per share. About 189,347 shares traded hands or up 408.07% from the average. ADMP has risen 10.81% since April 29, 2015 and is currently uptrending. It has outperformed the S&P500 by 11.01%.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The company has a market cap of $71.90 million. The Firm is developing various products in the allergy and respiratory markets The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe , APC-5000 dry powder inhaler (DPI), APC-1000, APC-2000 and APC-3000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. It currently has negative earnings. The Company’s product candidates for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are APC-5000 DPI and APC-1000.